Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ZS Ph2/3 Dose-response Study in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03127644
Recruitment Status : Completed
First Posted : April 25, 2017
Results First Posted : May 20, 2019
Last Update Posted : May 20, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
To assess efficacy of 5 g three times daily (TID) and 10 g TID ZS versus placebo in Japanese patients with hyperkalemia (serum potassium [S-K] ≥ 5.1 mmol/L and ≤ 6.5 mmol/L).

Condition or disease Intervention/treatment Phase
Hyperkalemia Drug: Sodium Zirconium Cyclosilicate (ZS) 5g Drug: Sodium Zirconium Cyclosilicate (ZS) 10g Drug: Placebo Phase 2 Phase 3

Detailed Description:

Patients not receiving any therapy for hyperkalemia and with 2 consecutive i-STAT potassium values of ≥ 5.1 mmol/L and ≤ 6.5 mmol/L will be enrolled and randomized 1:1:1 to receive ZS 5 g, ZS 10 g, or placebo TID for 48 hours.

Throughout the study most potassium values will be measured at fasting before taking study drug. Nothing should be taken by mouth except water, coffee or tea, with or without milk and/or sugar, and essential medications, prior to the blood collection for a minimum of 8 hours. Potassium level should be determined by both i-STAT and the Central Laboratory on all occasions. Treatment decisions (eg, stopping rules) will be made based on i-STAT potassium values, as these provide clinical sites with a real-time measurement. Statistical analyses on the study data will in principle be based on S-K values as measured by the central laboratory.

Safety and tolerability will be assessed on an ongoing basis. Standard study assessments including blood potassium, clinical chemistry (including calcium, magnesium, sodium, phosphate, creatinine, bicarbonate, and blood urea nitrogen [BUN]) and hematology parameters, urinalysis, vital signs, physical examinations, and electrocardiograms (ECGs) will be assessed during the study at the time points specified in the assessments schedule. All women of childbearing potential will have a urine pregnancy test prior to enrollment and at their End of Study (EOS) visit.

Stopping rules will be implemented to ensure subjects discontinue the study treatment and receive alternative therapy in case of significant hyperkalemia, hypokalemia, or significant cardiac arrhythmias.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 103 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia
Actual Study Start Date : June 14, 2017
Actual Primary Completion Date : February 23, 2018
Actual Study Completion Date : February 23, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Potassium
Drug Information available for: Zirconium

Arm Intervention/treatment
Experimental: Sodium Zirconium Cyclosilicate (ZS) 5g
Suspension administered 5g orally three times daily for 48 hours.
Drug: Sodium Zirconium Cyclosilicate (ZS) 5g
Suspension administered 5g orally three times daily for 48 hours.

Experimental: Sodium Zirconium Cyclosilicate (ZS) 10g
Suspension administered 10g orally three times daily for 48 hours.
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g
Suspension administered 10g orally three times daily for 48 hours.

Placebo Comparator: Placebo
Placebo suspension administered orally placebo three times daily for 48 hours.
Drug: Placebo
Placebo suspension administered orally placebo three times daily for 48 hours.




Primary Outcome Measures :
  1. Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment [ Time Frame: From 0 to 48 hours. ]

    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory.

    Natural logarithm of S-K from 0 to 48 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.



Secondary Outcome Measures :
  1. Percentage of Patients Who Achieved Normokalaemia at 48 Hours [ Time Frame: At 48 hours. ]
    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 48 hours after start of dosing was determined. Patients with missing S-K values at 48 hours were regarded as not normokalaemic.

  2. Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment [ Time Frame: From 0 to 24 hours. ]
    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed at the Central Laboratory. Natural logarithm of S-K from 0 to 24 hours post dose are modelled by the random coefficients model including fixed effects of intercept, time, time x treatment and patient-level random effects for time and intercept. Exponential rate of change refers to the slope estimate from the random coefficients model.

  3. Percentage of Patients Who Achieved Normokalaemia at 24 Hours [ Time Frame: At 24 hours. ]
    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at 24 hours after start of dosing was determined. Patients with missing S-K values at 24 hours were regarded as not normokalaemic.

  4. Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point [ Time Frame: From baseline to end of study (9 days). ]
    The percentage of patients who achieved normokalaemia (normalisation of S-K values to between 3.5 mmol/L and 5.0 mmol/L, inclusive) at each each scheduled potassium assessment time point after the start of dosing was determined. Patients with missing S-K values were regarded as not normokalaemic.

  5. Mean Change From Baseline in S-K Values at All Measured Time Intervals [ Time Frame: From baseline to end of study (9 days). ]
    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean change from baseline is displayed.

  6. Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals [ Time Frame: From baseline to end of study (9 days). ]
    Blood samples for determination of potassium were collected pre-dose, and at 1, 2, and 4 hours post Dose 1 on Day 1. An additional sample was collected at 90 minutes post Dose 2 on Day 1 if i-STAT potassium values at the 4-hour post Dose 1 time point was ≥ 6.1 or <4.0 mmol/L. On Day 2 samples were analysed pre-dose, and 1 and 4 hours post Dose 1. S-K levels were analysed locally using i-STAT devices, and at the Central Laboratory. S-K values measured at each time point and end of study visit were recorded and mean percent change from baseline is displayed.

  7. Time to Normalisation in S-K Values [ Time Frame: From 0 to 48 hours. ]
    The distribution of time to normalisation of S-K values (defined as S-K values between 3.5 mmol/L and 5.0 mmol/L, inclusive) was measured. A patient who reached at least one S-K within normal range was counted as an event regardless of S-K value after that time point. Patients who did not achieve normokalaemia within 48 hours were censored.

  8. Time to a Decrease in S-K Levels of 0.5 mmol/L [ Time Frame: From 0 to 48 hours. ]
    The median time (hours) for S-K values to decrease by 0.5 mmol/L was measured.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures.
  • Patients aged ≥18. For patients aged <20 years, a written informed consent should be obtained from the patient and his or her legally acceptable representative.
  • Two consecutive i-STAT potassium values, measured 60 (± 10) minutes apart, both values should be ≥ 5.1 mmol/L and ≤ 6.5 mmol/L and measured within 1 day before the first dose of study drug on Study Day 1.
  • Ability to have repeated blood draws or effective venous catheterization.
  • Female patients must be 1 year post-menopausal, surgically sterile, or using an acceptable method of contraception (an acceptable method of contraception is defined as a barrier method in conjunction with a spermicide) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of ZS/matching placebo to prevent pregnancy. In addition, oral contraceptives, approved contraceptive implant, long-term injectable contraception, intrauterine device, or tubal ligation are allowed. Oral contraception alone is not acceptable; additional barrier methods in conjunction with spermicide must be used.

Exclusion Criteria:

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Cause or symptoms of pseudohyperkalemia, such as

    1. hemolyzed blood specimen due to excessive fist clenching to make veins prominent
    2. hemolyzed blood specimen due to difficult or traumatic venepuncture
    3. history of severe leukocytosis or thrombocytosis
  • Patients treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of study drug on Study Day 1
  • Patients treated with resins (such as sevelamer hydrochloride, sodium polystyrene sulfonate [SPS; e.g. Kayexalate®] or calcium polystyrene sulfonate [CPS]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug
  • Patients with a life expectancy of less than 3 months
  • Patients who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the patients' tasks associated with the protocol
  • Female patients who are pregnant, lactating, or planning to become pregnant
  • Patients who have an active or history of diabetic ketoacidosis
  • Presence of any condition which, in the opinion of the investigator, places the patient at undue risk or potentially jeopardizes the quality of the data to be generated
  • Known hypersensitivity or previous anaphylaxis to ZS or to components thereof
  • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry
  • Patients with cardiac arrhythmias that require immediate treatment
  • Patients on dialysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03127644


Locations
Layout table for location information
Japan
Research Site
Chiba-shi, Japan, 260-8712
Research Site
Chiba-shi, Japan, 263-0043
Research Site
Hanyu-shi, Japan, 348-8505
Research Site
Higashiibaraki-gun, Japan, 311-3193
Research Site
Hitachinaka-shi, Japan, 312-0057
Research Site
Ina-shi, Japan, 396-8555
Research Site
Kagoshima-shi, Japan, 892-8580
Research Site
Kahoku-gun, Japan, 920-0293
Research Site
Kamakura-shi, Japan, 247-8533
Research Site
Kanazawa-shi, Japan, 920-8650
Research Site
Kasugai-shi, Japan, 486-8510
Research Site
Kawachinagano-shi, Japan, 586-8521
Research Site
Kawasaki-shi, Japan, 216-8511
Research Site
Kitakyushu-shi, Japan, 802-0001
Research Site
Koga-shi, Japan, 306-0041
Research Site
Kusatsu-shi, Japan, 525-8585
Research Site
Matsudo-shi, Japan, 271-0077
Research Site
Matsuyama-shi, Japan, 791-8026
Research Site
Nagoya-shi, Japan, 457-8511
Research Site
Naka-shi, Japan, 311-0113
Research Site
Omura-shi, Japan, 856-8562
Research Site
Shimajiri-gun, Japan, 901-0493
Research Site
Shizuoka-shi, Japan, 421-0117
Research Site
Yao-shi, Japan, 581-0011
Research Site
Yotsukaido-shi, Japan, 284-0027
Sponsors and Collaborators
AstraZeneca
  Study Documents (Full-Text)

Documents provided by AstraZeneca:
Study Protocol  [PDF] September 26, 2017
Statistical Analysis Plan  [PDF] February 19, 2018


Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03127644     History of Changes
Other Study ID Numbers: D9482C00002
First Posted: April 25, 2017    Key Record Dates
Results First Posted: May 20, 2019
Last Update Posted: May 20, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperkalemia
Water-Electrolyte Imbalance
Metabolic Diseases